论文部分内容阅读
美国纽约消息:在炎痛喜康临床展望专题讨论会上,一些专家们报告了非类固醇抗炎药(NSALD)炎痛喜康广泛用于治疗关节炎的安全性和有效性。来自耶鲁等6所大学的风湿病专家报告了对75,000多名病人十年多的研究结果,表明炎痛喜康安全、有效并能很好耐受。来自美国、加拿大和欧洲的100多名著名专家参加了Pfizer实验室主持的这次专题讨论会。根据最近发表的有关炎痛喜康副作用的报告,专题讨论会提出了证据认为,自发报告的药物副作用(ADR)不能用于形成有效的对比资料。类似的严格对照的对比试验巳表明炎痛喜康具有与其它NSALD相似的副作用。同样,在包括有几十万病人的公开
NEW YORK, USA (Reuters Health) - At the Symptomatic Symposium on Inflammation and Symptoms, a group of experts reported on the safety and efficacy of non-steroidal anti-inflammatory drugs (NSALD), piroxicam, widely used in the treatment of arthritis. Rheumatologists from six universities in Yale reported more than 10 years of research on more than 75,000 patients, indicating that inflammatory pain is safe, effective and well tolerated. More than 100 renowned experts from the United States, Canada and Europe participated in the symposium hosted by Pfizer Labs. Based on a recently published report on the side effects of piroxicam, the symposium presented evidence that spontaneously reported drug side effects (ADRs) can not be used to create effective contrast data. Similar rigorous comparative studies have shown that yokatoxin has similar side effects as other NSALDs. Similarly, the disclosure includes hundreds of thousands of patients